To evaluate the therapeutic efficacy of peptide-induced CTL responses in human tumor xenograft animal models, purified CD8+ T cells from peptide immunized HLA-A2 Tg mice were then intravenously transferred into SCID mice bearing H2981 tumors on day 7. This evidence concerns the gene CD8A and neoplasm.